Filing summary
Entity and period: The supplied filing is GlycoMimetics, Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 3, 2022—not a Crescent Biopharma filing. The company is a clinical-stage biotechnology developer of glycomimetic drugs; it had no approved products or product-sales revenue.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $1.16 million | $10.16 million |
| Research and development expense | $47.49 million | $44.93 million |
| General and administrative expense | $17.12 million | $16.74 million |
| Net loss | $63.43 million | $51.03 million |
| Net loss per share, basic and diluted | $1.23 | $1.12 |
| Net cash used in operating activities | $57.49 million | $39.24 million |
| Cash and cash equivalents at year-end | $90.25 million | $137.04 million |
- 2021 revenue was primarily $1.1 million from clinical-supply sales to Apollomics. 2020 included a $9.0 million upfront license payment and a $1.0 million development milestone, as well as supply revenue.
- Operating loss was $63.45 million in 2021 versus $51.51 million in 2020. Net loss increased 24%; loss per share increased from $1.12 to $1.23.
- R&D expense rose 6%, mainly from the uproleselan Phase 3 trial and manufacturing validation batches, partly offset by lower personnel and stock compensation expense. G&A rose 2%. No meaningful operating margin is presented for this development-stage company.
- Operating cash outflow increased by $18.25 million year over year. Financing provided $10.72 million in 2021, mainly from at-the-market stock sales; investing used $0.01 million. Cash declined $46.78 million during the year.
- The company reported no borrowings. Year-end liabilities were $12.74 million, including $1.92 million of lease liabilities; current liabilities were $11.82 million. Stockholders’ equity was $81.60 million.
- GlycoMimetics sold 3.09 million shares under its ATM facility in 2021 for net proceeds of $10.70 million. Approximately $85.1 million remained available under the facility at year-end, subject to market conditions and other limitations.
Business developments, outlook and risks
- Uproleselan: Enrollment in the 388-patient Phase 3 trial for relapsed/refractory AML was completed in November 2021. The company expected preliminary results after year-end 2022. Enrollment in the Phase 2 portion of an NCI-sponsored Phase 2/3 trial in previously untreated older adults was completed in December 2021; an interim event-free-survival analysis was planned to determine whether the study should proceed to Phase 3.
- Other programs: The Phase 1b GMI-1359 breast-cancer study ended in the fourth quarter of 2021; further indications and funding needs remained under evaluation. The company planned to submit an IND for GMI-1687 in the first half of 2022. Galectin-3 inhibitors remained preclinical.
- Management outlook: Management estimated that year-end cash would fund operating expenses and capital requirements into the second quarter of 2023, based on assumptions that could prove incorrect. The company expected continued operating losses and said it would need additional capital.
- Going concern: Despite the estimated runway, management and the auditor disclosed substantial doubt about the company’s ability to continue as a going concern beyond one year after issuance of the financial statements without additional financing or another funding arrangement. No committed external financing source was disclosed. Failure to raise capital could force delays, reductions or termination of programs.
- Apollomics agreement: Apollomics holds Greater China rights to uproleselan and GMI-1687 and is responsible for regional development costs. GlycoMimetics may receive up to approximately $179 million in additional milestones and tiered royalties, but these are contingent and uncertain; no milestone revenue was recognized in 2021.
- Key risks and unusual items: Clinical success and regulatory approval are uncertain; the business relies on third-party manufacturers and trial providers; COVID-19 previously slowed trial-site initiation and enrollment; and future equity financing could dilute shareholders. The auditor identified accrued clinical-trial expenses as a critical audit matter: year-end accrued expenses totaled $8.7 million, including estimated clinical costs. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-controls attestation.
Important facts for investors to verify
- Confirm the filing identity: the document is GlycoMimetics, Inc. (Nasdaq: GLYC), not Crescent Biopharma, Inc.
- Check subsequent uproleselan Phase 3 results and the NCI-sponsored trial’s interim analysis against the expectations stated in this 10-K.
- Assess actual cash use, financing raised, and whether the stated runway or going-concern position changed after December 31, 2021.
- Verify progress, costs, and potential milestone or royalty receipts under the Apollomics agreement, including the planned GMI-1687 IND filing.
- Review the complete financial statements and notes for clinical-trial accrual estimates, ATM issuance and dilution, and lease obligations.